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Abstract
Background: Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for
individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes,
on liver pathology in a non-diabetic NASH mouse model.
Methodology/Principal Findings: Eight-week-old C57BL/6 mice were fed a methionine- and choline-deficient plus high fat
(MCD+HF) diet with or without 0.1% metformin for 8 weeks. Co-administration of metformin significantly decreased fasting
plasma glucose levels, but did not affect glucose tolerance or peripheral insulin sensitivity. Metformin ameliorated MCD+HF
diet-induced hepatic steatosis, inflammation, and fibrosis. Furthermore, metformin significantly reversed hepatic steatosis
and inflammation when administered after the development of experimental NASH.
Conclusions/Significance: These histological changes were accompanied by reduced hepatic triglyceride content,
suppressed hepatic stellate cell activation, and the downregulation of genes involved in fatty acid metabolism,
inflammation, and fibrogenesis. Metformin prevented and reversed steatosis and inflammation of NASH in an experimental
non-diabetic model without affecting peripheral insulin resistance.
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Introduction
Nonalcoholic steatohepatitis (NASH) refers to a stage within the
spectrum of nonalcoholic fatty liver disease (NAFLD) character-
ized by hepatic steatosis, inflammation, and fibrosis, and is
emerging as one of the most common liver diseases and a leading
cause of cryptogenic cirrhosis [1].
While searching for clinical factors predicting outcomes from
liver fibrosis, a key feature associated with the progression of
cirrhosis and hepatocellular carcinoma, we found that tight
glycemic control by diet or bolus-first insulin therapy ameliorated
liver fibrosis [2]. Indeed, diabetes is an independent risk for the
progression of liver fibrosis in hepatitis C [3]. Experimentally,
diabetes accelerates the pathology of steatohepatitis in the type 2
diabetic rat model OLETF fed a methionine and choline-deficient
diet [3]. These findings suggest that a diabetic state itself is an
added risk for liver fibrosis. From this perspective, the insulin
sensitizing anti-diabetic agent pioglitazone ameliorates NASH
pathology in patients with type 2 diabetes [4]. However, the effects
of pioglitazone on liver pathology seem only marginal in non-
diabetic patients with NASH [5]. Furthernore, both vitamin E and
pioglitazone failed to improve hepatic fibrosis in non-diabetic
patients with NASH [6]. This study again stated that additional
anti-fibrogenic therapy should be required in non-diabetic patients
with NASH.
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The anti-diabetic drug metformin restrains hepatic gluconeo-
genesis through pleiotropic effects including activation of AMP-
activated protein kinase (AMPK) [7], suppression of glucose-6-
phosphatase expression [8], and inhibition of mitochondrial
oxidative phosphorylation [9], which may play a pivotal role in
glucose and lipid metabolism in the liver [10,11]. We previously
performed a DNA microarray analysis on the livers of obese
diabetic db/db mice 2 h after a single administration of metformin
and showed that metformin altered the expression level of multiple
genes linked to glucose and lipid metabolism in the liver [12]. In
vitro studies suggest that AMPK suppresses proliferation and
activation of hepatic stellate cells by inhibiting Akt, inducing
antioxidant enzymes, and blocking the cell cycle [13,14].
However, evidence for the use of metformin in the treatment of
NAFLD is still limited to hepatic steatosis [15–17], and the effects
of metformin on hepatic inflammation and fibrosis, key histolog-
ical features of NASH, remains unclear. In the present study, we
assessed whether metformin ameliorated and/or reversed inflam-




The animal study was carried out in accordance with the
Guidelines on the Care and Use of Laboratory Animals issued by
Kanazawa University. The protocol was approved by the ethical
committee of Kanazawa University (Approval NO. 070816). All
surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Animal model and experimental design
Eight-week-old C57BL/6 mice were obtained and housed in a
room under controlled temperature (25uC), humidity, and lighting
(12/12-h artificial light/dark cycle). Animals were given free access
to standard laboratory rat chow and tap water. C57BL/6 mice
were divided into three experimental groups and fed for 8 weeks as
follows: a) normal chow (NC, n=10), b) methionine- and choline-
deficient diet (MCD)+high fat (HF) diet (Oriental Yeast Co.,
Tokyo, Japan; MCD, fat 60%, n=20), c) MCD+HF diet mixed
with 0.1% metformin (MCD+Met, fat 60%, n=25). In our
previous study [3], we established a dietary rodent model of
steatohepatisis associated with insulin resistance by feeding a
methionine choline-deficient and high fat diet (MCD+HF). This
model reveals only mild inflammation with no fibrosis at 4 weeks
and develops intense lobular inflammation and perivenular and
pericellular fibrosis prominently in liver at 8 weeks. Based on these
time course findings, we fed MCD+HF for 8 weeks to create the
advanced stages of steatohepatitis. We set the dose if metformin at
37.5 mg/kg of mouse weight, corresponding to 2250 mg/60 kg of
human. Calculated from daily food intake and body weight of the
mice fed the MCD+HF diet, we mixed metformin at 0.1% in
MCD+HF diet. The weights and food intakes in each group of rats
were recorded every week. All animal procedures were performed
in accordance with the standards set forth in the Guidelines for the
Care and Use of Laboratory Animals at the Takara-machi campus
of Kanazawa University
Effects of metformin on advanced stages of nonalcoholic
steatohepatitis were evaluated as follows. The MCD+HF diet
was fed to 8 week-old C57BL/6 mice for 8 weeks to create an
advanced non-alcoholic steatohepatitis model. Then, mice were
divided into two experimental groups that were fed for 4 weeks as
follows: d) MCD+HF (MCD, fat 60%, n=10), e) MCD+HF diet
mixed with 0.1% metformin (MCD+Met, fat 60%, n=10).
Blood sampling and analysis
Blood samples were obtained from the tail vein at 16 and 20
weeks of age under anesthesia after a 4-h fast. Blood glucose was
determined by the glucose-oxidase method using Freestyle (Kissei,
Nagano, Japan). Blood samples were centrifuged and plasma was
frozen at 280uC for subsequent measurement of the plasma
triglyceride, total cholesterol (TC), and insulin levels. Serum TC
and triglyceride concentrations were determined by an enzymatic
method using the Cholesterol E-test and Triglyceride E-test (Wako
Pure Chemical Industries, Osaka, Japan). Plasma insulin levels
were determined with an ELISA kit (Mercodia, Uppsala, Sweden).
Evaluation of Insulin Sensitivity
After 8 weeks, mice in all groups underwent an oral glucose
tolerance test after a 4-hour fast. Two grams of glucose per
kilogram of body weight was administered orally. Blood was
drawn from a tail vein at 0, 30, 60, and 120 minutes for
measurement of plasma glucose concentrations. An intraperitoneal
insulin tolerance test was per- formed after a 4-hour fast by
intraperitoneal administration of 0.5 unit insulin per kilogram of
body weight. Blood was drawn from a tail vein at 0, 15, 30, 45, 60,
and 120 minutes for measurement of plasma glucose concentra-
tions.
Measurement of liver triglyceride levels
Mice were sacrificed, and liver weight and the triglyceride
content in liver tissue were measured. To quantify hepatic
triglyceride content, the liver was lysed with buffer from a
commercially available kit (TG E-test; Wako) and disrupted by
sonication. The triglyceride content of the homogenate was then
determined with the above kit, according to the manufacturer’s
instructions.
Histological evaluation and immunohistochemistry
After 8, 10, and 12 weeks on each diet, animals were sacrificed
and their livers were fixed in 10% buffered formalin and
embedded in paraffin. The severity of hepatic histologic changes
was assessed in hematoxylin and eosin- and Sirius red stained
samples and blindly scored by a single pathologist who was
unaware of the treatments for mice. Steatosis, inflammation, and
fibrosis were semi-quantitatively evaluated according to the
standard criteria of NASH grading and staging with minor
modifications [18]. The degree of steatosis was scored as the
percentage of hepatocytes containing lipid droplets. Inflammation
was scored as: 0, no hepatocyte injury and inflammation, 1, mild
focal injury, 2, noticeable injury, and 3, severe zone 3 hepatocyte
injury and inflammation. Fibrosis was scored as: 0, no fibrosis, 1,
pericellular and perivenular fibrosis, 2, focal bridging fibrosis, 3,
extensive bridging fibrosis with lobular distortion, and 4, cirrhosis.
Images of the histological slices of Sirius red stain were analyzed
and captured under 1006 magnification. Further Area of their
fibrosis was morphometrically and statistically analyzed with
Image J and SPSS software [19].
Slides were immunostained with monoclonal mouse anti-human
a-smooth muscle actin (a-SMA) (Dako, Kyoto, Japan). This was
followed by use of the immunoperoxidase technique using an
Envision kit (Dako). Further their area of a-SMA was morpho-
metrically and statistically analyzed with Image J and SPSS
software [19].
Hydroxyproline Assay
Hydroxyproline content of the liver was measured by a
spectrophotometric assay as an assessment of liver collagen
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content. Liver tissue was homogenized in ice-cold distilled water
(1 mL) using a polytron homogenizer. Subsequently, 125 mL of
50% trichloroacetic acid was added, and the homogenates were
further incubated on ice for 30 minutes. Precipitated pellets were
hydrolyzed for 24 hours at 110uC in 6N HCL.
After hydrolysis, the samples were filtered and neutralized with
10N NaOH, and the hydrolysates were oxidized with Chloramine-
T (Sigma) for 25 minutes at room temperature. The reaction
mixture was then incubated in Ehrich’s perchloric acid solution at
65uC for 20 minutes and cooled to room temperature. Sample
absorbance was measured at 560 nm. Purified hydroxyproline
(Sigma) was used to set a standard. Hydroxyproline content was
expressed as micrograms of hydroxyproline per gram liver [20].
Real-time quantitative PCR
Total RNA was extracted from each liver using the RNeasy
Mini kit (Qiagen, Tokyo, Japan), as described previously [21].
Real-time quantitative polymerase chain reaction (PCR) was
performed for transforming growth factor-b (Tgfb), a1(I) procol-
lagen a2 (Col1a2), plasminogen activator inhibitor-1 (PAI-1:
encoded by Serpine-1 gene), sterol regulatory element-binding
protein-1c (Srebp1c), fatty acid synthase (Fas), cytochrome P450 2e1
(Cyp2e1), apolipoprotein B (Apob), microsomal triglyceride transfer
protein (Mttp) and hemeoxygenase (Hmox1) mRNA using the ABI
Prism 7900 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). The primer sets and TaqMan probes for
Col1a2, Serpine1, Fas, Cyp2e1, Apob, Mttp and Hmox1 are proprietary
to Applied Biosystems (Assay-on-Demand gene expression prod-
uct). The primer sets and TaqMan probes for Tgfb and Srebp1c
were designed with Primer Express (ver. 1.5; Applied Biosystems).
The forward primers were 59-TTCCTGGCGTTACCTTGGT-
39 for Tgfb and 59-GGGCAGCTCTGTACTCCTTCAA-39 for
Srebp1c. The reverse primers were 59-GCCACTGCCGGA-
CAACT-39 for Tgfb and 59-GCTAAGCTGTCCCGCAGGTA-
39 for Srebp1c. The TaqMan probes were 59-TACGCCT-
GAGTGGCTGTCTTTTGA-39 for Tgfb and 59-AGCCAGCC-
TGGCCATCTGTGAGA-39 for Srebp1c. The amount of DNA
available for PCR in the different samples and target gene
sequence expression were normalized with respect to the
expression of an endogenous control, 18S ribosomal RNA (18S
rRNA TaqMan Control Reagent kit; Applied Biosystems)(Col1a2,
Serpine1, Fas, Cyp2e1, Tgfb and Srebp1c) and beta-actin (TaqMan
Control Reagent kit; Applied Biosystems) (Apob, Mttp). The PCR
conditions were one cycle at 50uC for 2 min and 95uC for 10 min,
followed by 50 cycles at 95uC for 15 s and 58uC for 1 min.
Western blotting
Western blotting was performed with iBlot Western Detection
Kit (life technologies) as we previously reported [22]. The antibodies
for PAI-1, FAS and APOB were purchased from Abcam.
DNA microarray analysis
A DNA microarray analysis was performed with an Affymetrix
GeneChip (Mouse Genome 430 2.0 Array; Affymetrix, Santa Clara,
Figure 1. Intraperitoneal glucose tolerance test (A) and insulin tolerance test (B). Black line, methionine- and choline-deficient+high fat
diet (MCD+HF, n= 15). Short dashed line, MCD+HF diet mixed with 0.1% metformin (MCD+Met; n= 20). *p,0.05, vs. MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g001
Table 1. Metabolic parameters in the methionine- and
choline- deficient (MCD) diet-induced mice of nonalcoholic
steatohepatitis after 8 weeks of metformin (Met) treatment.
Parameters MCD+HF MCD+HF+Met
Body weight (g) 15.260.2 14.660.3
Liver weight (mg) 811631 638633*
Food consumption (mg/day) 214615 204643
Fasting blood glucose (mg/dL) 63.768.9 51.164.7*
Fasting serum insulin (pg/mL) 495617 550644
Fasting serum triglycerides (mg/dL) 47.963.2 49.862.6
Serum total cholesterol (mg/dL) 20.860.8 47.461.9*
Data are means 6 standard error of the mean.
*p,0.05 versus untreated Met diet fed mice.
doi:10.1371/journal.pone.0043056.t001
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CA, USA). Briefly, 2 mg of total RNA was used as a template for
cDNA synthesis with the GeneChip Expression 39-Amplification
One-Cycle cDNA Synthesis kit (Affymetrix), and biotin-labeled
cRNA was synthesized with GeneChip Expression 39-Amplification
Reagents (Affymetrix). After generating the hybridization cocktails,
hybridization to the DNAmicroarray and fluorescent labelling were
performed with a GeneChip Hybridization Wash and Stain kit
(Affymetrix). The microarrays were subsequently scanned with the
GeneChip Scanner 3000 MegAllele System (Affymetrix). Our DNA
chip data was accepted as approval number GSE35961 in GEO
(Gene Expression Omnibus).
Microarray data analysis
Data analysis was conducted with the GeneChip Operating
System 1.1 (Affymetrix). Detection, signal, signal log ratio, and
change were obtained from the GeneChip Operating System
(GCOS) with default settings after global normalization was
performed to make the average intensity of all probe sets equal to
100. The fold-change value was calculated from the signal log
ratio. Probe sets with expression changes labelled as change call
‘‘I’’ or ‘‘D’’ by GCOS were referred to as ‘‘regulated probe sets.’’
‘‘Regulated probe sets’’ with more than a 1.5-fold difference in
expression were extracted to choose differentially expressed probe
sets among the 45,101 probe sets represented on the array. Among
them, the probe sets showing significant expression changes
(p,0.05; Student’s t-test) in the analysis of individual samples
(n=4) were chosen for further analysis.
Principal component analysis (PCA) or hierarchal clustering was
performed with Spotfire DecisionSite 9.1 (Spotfire, Somerville,
MA, USA).
Figure 2. Metformin ameliorated the pathology in a non-alcoholic steatohepatitis dietary model. Representative photomicrographs
show the effects of normal chow (NC, n= 10), the methionine- and choline-deficient+high fat diet (MCD+HF, n= 15), and the MCD+HF diet mixed with
0.1% metformin (MCD+HF+Met; n= 20) on the liver histology in C57BL/6 mice. Mice were fed the diets for 8 weeks. Paraffin-embedded sections were
stained with (A) hematoxylin and eosin or (B) sirius red and (C) immunohistochemically stained with anti-a-smooth muscle actin. Bar, 20 mm. Original
magnification,6100. (D) Blinded observers scored the hematoxylin-and-eosin-stained sections for steatosis and inflammation severity; azan-stained
samples were scored for fibrosis. The scoring criteria are described in the Materials and Methods. Values are means 6 standard error of the mean.
*p,0.05, vs. MCD+HF diet group. (E) Hepatic hydroxyproline (F) morphometric analysis of liver fibrosis of sirius red stain (G) Metformin improved
hepatic triglyceride content in diet-induced non-alcoholic steatohepatitis model mice. (H) Area of a-SMA. Black bar, normal chow (NC, n = 10). White
bar, the methionine- and choline-deficient+high fat diet (MCD+HF, n= 15). Mosaic Bar, the MCD diet mixed with 0.1% metformin (MCD+HF+Met;
n= 20). Values are the mean 6 standard error. *p,0.05, vs. normal chow. **p,0.05, vs. the MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g002
Figure 3. Comprehensive gene expression analyses in livers of mice treated with metformin. (A) Gene expression profile analysis using
materials from individual animals and performed unsupervised hierarchical clustering of all sets of expression data with the 792 genes. The results
clearly showed that mice that had been treated with metformin were clustered together with normal chow and could be separated from no
treatment. (B) Principal component analysis using the same 792 genes dataset showed a remarkable shift in the distribution of mice treated with
metformin compared with no treatment. Green, normal chow group; Red, the methionine- and chorine-deficient (MCD) diet+high fatgroup; Blue, the
MCD+HF diet mixed with 0.1% metformin group. (C) Gene-to-gene network analysis was used to investigate molecular relationships between
differentially expressed genes included in Hepatic Fibrosis/Hepatic Stellate Cell Activation pathway. Red asterisk (*): NASH related genes. Pink asterisk
(*): hepatic fibrosis related genes. Red: genes up-reguleted by metformin treatment. Blue: genes down-regulated by metformin treatment.
doi:10.1371/journal.pone.0043056.g003
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Canonical pathway analysis/gene-to-gene network
analysis
Canonical pathway and gene-to-gene network analyses were
performed using Ingenuity Pathways Analysis (ver. 5.5.1;
Ingenuity Systems, www.ingenuity.com, Redwood City, CA,
USA). The extracted data set containing differentially expressed
probe sets and corresponding values of the signal log ratio was
uploaded into the application. Each probe set was mapped to its
corresponding gene object in the Ingenuity Pathways Knowledge
Base.
A canonical pathway analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the differentially expressed genes. Genes
that were associated with a canonical pathway in the Ingenuity
Pathways Knowledge Base were considered for analysis. The
significance of the association between the genes and the canonical
pathway was measured in two ways: 1) the ratio of the number of
genes from the data set that map to the pathway divided by the
total number of genes that map to the canonical pathway is
displayed, and 2) Fischer’s exact test was used to calculate a p-
value determining the probability that the association between the
genes in the dataset and the canonical pathway was explained by
chance alone. Canonical pathways associated with the differen-
tially expressed genes were extracted with the calculated p-value
cut-off of 0.05.
Statistical analysis
All results are expressed as the mean 6 standard error of the
mean. Data were analyzed using a one-factor analysis of
variance to compare the means of all groups. Between-two
group differences in continuous variables were assessed by a
univariate analysis with Student’s t-test. One-way ANOVA was
used for the comparison of more than two groups, followed by
Tukey-Kramer post hoc test. P-value,0.05 was considered to
indicate statistical significance. All calculations were performed




Body and liver weights and lipid levels after 8 weeks in each
group are shown in Table 1. Co-administration of metformin did
not affect body weight, physical appearance, or behavior of the
mice. Amount of food consumption was also unchanged between
MCD+HF groups and MCD+HF+Met groups. Metformin
significantly decreased the liver weights in mice that received the
MCD+HF diet (p,0.05, vs. mice fed MCD+HF diet) without
affecting body weight. Co-administration of metformin increased
serum TC levels. Metformin decreased fasting blood glucose levels
without affecting serum insulin levels (Table 1). We conducted
intraperitoneal glucose and insulin tolerance tests at 8 weeks to
evaluate the effect of metformin on glucose tolerance and insulin
sensitivity, respectively (Fig. 1). Although basal glucose levels were
significantly lower in mice treated with metformin, the glucose
increase after a glucose challenge and the glucose decrease after an
insulin challenge did not differ between the groups. These findings
suggest that metformin exerts a minimum effect on glucose
tolerance and insulin sensitivity in this non-diabetic mouse model
of steatohepatitis.
Metformin ameliorates liver pathology in a NASH dietary
mouse model
The histological findings at 8 weeks of treatment are shown in
Fig. 2A and B. The MCD diet caused marked macrovesicular
steatosis with focal lymphocytic infiltration, hepatocellular drop-
outs, intense lobular inflammation, and prominent perivenular
and pericellular fibrosis in zone 3 of the 8-week-old mice livers.
The histological score based on the current diagnostic criteria at
8 weeks of treatment is summarized in Fig. 2D. Co-administra-
tion of metformin significantly ameliorated the MCD diet-
induced steatosis, inflammation, and fibrosis. Moreover, metfor-
min inhibited the elevation of hepatic hydroxyproline contents
induced by MCD+HF diet (Fig. 2E). In addition, metformin
decreased the positive area of Sirius Red stain, a representative
staining for the connective tissues (Fig. 2F). Indeed, metformin
Table 2. Canonical pathways analysis identified the pathways from the Ingenuity Pathways Analysis library of canonical pathways
were most significant to the differentially expressed genes.
Pathway
1.5 fold up-regulated gene
(MCD+HF+Met vs MCD+HF)
1.5 fold down-regulated gene
(MCD+HF+Met vs MCD+HF) 2log10(p value)
Complement and Coagulation Cascades MBL2, C9 C3AR1 6.21
Leukocyte Extravasation Signaling - MMP12, ARHGAP9, ITGB2, CYBB, CYBA,
CD44, RAC2, TIMP3, MSN, TIMP2
4.07
Acute Phase Response Signaling SERPING1, MBL2, C4B, LBP C9 JUN, HMOX1, PAI1, TNFRSF1B, TF 2.76
Hepatic Fibrosis/Hepatic Stellate Cell
Activation
LBP COL1A2, EDNRB, HGF, CTGF, TIMP2,
TNFRSF1B, IGFBP3
2.76
Linoleic Acid Metabolism CYP2B10, CYP2B13, CYP2C38 CYP4A12, CYP1B1 2.47
LPS/IL-1 Mediated Inhibition of RXR
Function
ABCC4, FMO2, FABP4, TNFRSF1B GSTT1, FABP7, LBP, JUN, ACOX1 2.37
Antigen Presentation Pathway - HLA-DQB2, CD74, HLA-DQA1 2.07
Tryptophan Metabolism CCBL1, CYP2C44, CYP2C70, CYP2C50, HAAO CYP1B1 1.76
Arachidonic Acid Pathway CYP2C44, CYP2C70, PLA2G12B, CYP2C50 PLA2G4A, CYP1B1 1.68
PPARa/RXRa Activation CYP2C44, CYP2C70, CYP2C50 ADCY7, JUN, LPL, ACOX1 1.60
Metabolism of Xenobiotics by
Cytochrome P450
CYP2C44, CYP2C70, CYP2C50, GSTT1 CYP1B1 1.54
doi:10.1371/journal.pone.0043056.t002
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treatment significantly improved MCD diet-induced hepatic
triglyceride accumulation in C57BL/6 mice (Fig. 2G).
Metformin decreases activated stellate cells and
downregulates mRNA expression of fibrogenic genes in a
NASH dietary mouse model
We performed an immunohistochemical analysis of a-SMA
after 8 weeks to investigate the activation of hepatic stellate cells,
which play central roles in liver fibrosis. Representative photomi-
crographs of liver sections stained with anti-a-SMA antibody are
shown in Fig. 2C. Activated stellate cells, which express a-SMA
and are therefore also called myofibroblast-like cells, showed
prominent proliferation in the liver of mice fed the MCD diet.
Metformin treatment reduced a-SMA-positive cells in the livers of
mice that received the MCD diet (Fig. 2H).
Global gene expression profile in the livers of individual
mice
This analysis identified 792 genes that showed at least a 1.5-fold
difference in expression following metformin treatment. We
performed a gene expression profile analysis using materials from
15 individual animals and performed unsupervised hierarchical
clustering of all 15 sets of expression data with the 792 genes to
examine the relevance of these subtle gene expression changes.
The results showed that mice treated with metformin were
clustered together with those who were fed normal chow and
Figure 4. Effects of metformin on expression of genes involved in steatosis, inflammation, and fibrosis in the liver of mice fed a
MCD+HF diet. Real-time quantitative polymerase chain reaction was used to measure the hepatic expression of genes encoding (A) sterol
regulatory element-binding protein-1c (Srebp1c), (B) fatty acid synthase (Fas), (C) apolipoprotein B (Apob), (D) microsomal triglyceride transfer protein
(Mttp), (E) plasminogen activator 1 (Serpine1), (F) cytochrome P450 2e1 (Cyp2e1), (G) transforming growth factor-b (Tgfb), (H) procollagen1a2 (Col1a2),
(I) hemeoxigenase1 (Hmox1). Results were normalized against 18S rRNA (Srebp1c, Fas, Serpine1, Cyp2e1, Tgfb, Col1a2, Hmox1) and beta-actin
(Apob,Mttp). Values are means 6 standard error. *p,0.05, vs. normal chow. **p,0.05, vs. MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g004
Metformin Reverses Inflammation in NASH
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e43056
could be separated from the untreated (Fig. 3A). Furthermore,
PCA using the same 792 genes data set showed a remarkable shift
in the distribution of mice treated with metformin compared with
untreated mice (Fig. 3B). Moreover, a canonical pathway analysis
of the expression profile revealed that metformin effected
significant alterations in gene expression across at least 11
metabolic pathways, including those involved in fatty acid and
amino acid metabolism (Table 2). A gene network based on
molecular relationships between differentially expressed genes
included in the hepatic fibrosis/hepatic stellate cell activation
pathway was built from the biological relationships stored in the
Ingenuity Pathways Knowledge Base (Fig. 3C). Metformin
treatment ameliorated activity in the hepatic fibrosis/hepatic
stellate cell activation pathway, such as Serpine-1, collagen Ia 2
(Col1a2), endothelin receptor type B (Ednrb), hepatic growth factor
(Hgf), connective tissue growth factor (Ctgf), tissue inhibitors of
matrix metalloproteinase (Timp), tumor necrosis factor receptor
superfamily 1B (Tnfrsf1b), and insulin like growth factor binding
protein 3 (Igfbp3). Metformin prevented expression of inflamma-
tion and fibrosis genes cooperatively as well as those of fatty acid
metabolism in the liver of the NASH dietary mouse model.
Metformin downregulates lipogenic and fibrogenic gene
expression in the NASH dietary mouse model
Because the gene expression profile results indicated that
metformin prevents the progression of NASH by altering genes
expressed during fibrosis and fatty acid metabolism, we assessed
the effect of metformin on mRNA expression of these genes by
real-time PCR. Metformin inhibited Fas hepatic mRNA expres-
sion to 60% in the livers of the NASH dietary mouse model
(p,0.05, vs. MCD diet; Fig. 4B). Metformin also inhibited hepatic
mRNA expression of Serpine1 to 42%, Cyp2e1 to 55%, and Col1a2
to 56% in the livers of MCD-induced steatohepatitis model mice
(p,0.05, vs. MCD diet; Fig. 4F, 4G and 4H). Moreover,
metformin also coordinately ameliorated downregulated genes for
oxidative stress-associated proteins, such as Hmox1, in the livers of
MCD-induced steatohepatitis model mice (p,0.05, vs. MCD diet;
Fig. 4I).
Metformin downregulates protein levels of PAI-1 in the
NASH dietary mouse model
Next, we examined protein levels of PAI-1, FAS, and APOB by
using Western blotting, Consistent with the result of realtime PCR,
protein levels of PAI-1 were significantly decreased by metformin
(Fig. 5A and 5B). However, FAS protein levels were not
significantly altered by metformin treatment.
Metformin reverses steatosis and inflammation of the
dietary mouse model in the advanced stages of NASH
To determine whether metformin improves pre-existing NASH
in mice, we examined the therapeutic effect of metformin on
advanced stage NASH in the model mice. The results of body and
liver weights and lipid levels after 4 weeks of treatment in each
group are shown in Table 3. Co-administration of metformin
inhibited weight gain and improved glycemic levels compared with
metformin-untreated mice. Serum insulin levels were similar in
each group. Food consumption was unchanged by metformin.
As shown in Fig. 6, metformin ameliorated macrovesicular
steatosis with focal lymphocytic infiltration and hepatocellular
drop-outs, and intense lobular inflammation at 4 weeks (Fig. 6D).
Liver fibrosis score (Fig. 6D) and area of a-SMA (Fig. 6F) were
unaffected. However, metformin significantly decreased the
positive area of Sirius Red staining (Fig. 6E). Metformin also
significantly improved MCD diet-induced hepatic triglyceride
accumulation in C57BL/6 mice (p,0.05, Fig. 6G).
Metformin inhibited hepatic mRNA expression of Srebp1c to
67% and that of Cyp2e1 to 45% in the livers of mice fed the MCD
diet (P,0.05, vs. MCD diet for both variables; Fig. 7A and 7F).
Moreover, metformin inhibited hepatic mRNA expression of Tgfb
to 33% and Col1a2 to 17% in the livers of mice fed the MCD diet
(P,0.05, vs. MCD diet for both variables; Fig. 7G and 7H).
Protein levels for PAI-1, FAS and APOB were unchanged by
metformin treatment (Fig. 8).
Discussion
Previous studies evaluating the effects of metformin on NAFLD
liver pathology are limited. In genetically obese model ob/ob
Figure 5. Effects of metformin on the levels of proteins
involved in lipid metabolism in the liver of mice fed a MCD+HD
diet. (A) Quantitative data from densitometric analysis of Western blots
from three samples. (B) Representative blots for PAI-1, FAS, and, APOB
are shown. GAPDH is used as a control for protein loading. Values are
the mean 6 standard error. *p,0.05 versus the MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g005
Table 3. Metabolic parameters in nonalcoholic
steatohepatitis model mice at 4 weeks of metformin (Met)
treatment after feeding 8-week-methionine- and choline-
deficient (MCD) diet.
Parameters MCD+HF MCD+HF+Met
Body weight (g) 14.660.8 12.560.7*
Liver weight (mg) 991658 838668*
Food consumption (mg/day) 206627 217613
Fasting blood glucose (mg/dL) 61.067.0 33.264.0*
Fasting serum insulin (pg/mL) 467637 490631
Fasting serum triglycerides (mg/dL) 47.662.9 49.363.9
Serum total cholesterol (mg/dL) 33.765.2 49.965.7*
Data are means 6 standard error of the mean.
*p,0.05 versus untreated Met diet fed mice.
doi:10.1371/journal.pone.0043056.t003
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Figure 6. Metformin reversed steatosis and inflammation of the advanced stages of nonalcoholic steatohepatitis in mice.
Representative photomicrographs show the effects of the methionine- and choline deficient plus high fat diet (MCD+HF, n = 10) and the MCD+HF
diet mixed 0.1% metformin (MCD+HF+Met; n = 10). Mice fed the diets for 4 weeks from the advanced stages of steatohepatitis. Paraffin-embedded
sections were stained with (A) hematoxylin–eosin, (B) Sirius Red and (C) immunohistochemically stained with anti-a-smooth muscle actin. Bar, 20 mm.
Original magnification,6100. (D) Metformin improved hepatic triglyceride content of diet-induced non-alcoholic steatohepatitis. Mice were fed the
methionine- and choline deficient+high fat diet (MCD+HF, n = 10) and the MCD+HF diet mixed 0.1% metformin (MCD+HF+Met; n = 10). Values are the
mean 6 standard error of the mean. *p,0.05 versus the MCD+HF diet. (E) Morphometric analysis of liver fibrosis of sirius red stain(%). (F) Area of
alpha-SMA(%). (G) Metformin improved hepatic triglyceride content of diet-induced non-alcoholic steatohepatitis. White Bar, continuous methionine-
and choline deficient+high fat diet (MCD+HF, n = 5). Mosaic Bar, the MCD+HF diet mixed 0.1% metformin (MCD+HF+Met; n = 10). Values are the mean
6 standard error. *p,0.05 versus the MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g006
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mice, Lin et al. reported that metformin was effective at reversing
fatty liver, probably via reduced hepatic expression of tumor
necrosis factor, which promotes hepatic lipid accumulation and
ATP depletion [15]. In humans, Marchesini et al. showed that long-
term metformin treatment significantly reduced mean transaminase
concentrations and decreased liver volume by 20% [16]. Although
metformin prevents fat accumulation in a simple fatty liver, whether
metformin ameliorates hepatic inflammation and fibrosis in
steatohepatitis remains unclear. We demonstrated that metformin
prevents and reverses pathological development in a NASH dietary
mouse model. This is the first experimental evidence that metformin
can prevent and reverse the development of not only steatosis but
also inflammation in the liver of a NASH model.
High levels of insulin cause fatty liver in insulin resistant states,
suggesting that mice with type 2 diabetes manifest selective
hepatic insulin resistance: insulin fails to suppress gluconeogen-
esis but continues to activate lipogenesis [23]. Whether
metformin improves insulin resistance remains controversial
[24,25]. Basu et al. reported that metformin at a dose of
2000 mg/day for 4 months did not improve insulin-induced
stimulation of glucose disappearance and did not improve
impairment of insulin-induced suppression of hepatic glucose
production [25]. Indeed, in the present study, metformin seemed
to exert a minimal effect on glucose tolerance and insulin
sensitivity, as shown by the intraperitoneal glucose and insulin
tolerance test results. Metformin significantly lowered fasting
glucose levels without altering fasting insulin levels, suggesting
that metformin directly suppressed hepatic gluconeogenesis
independently of an insulin signaling pathway, possibly by
activating AMPK [7,26].
Figure 7. Reverse effects of metformin on expression of genes involved in steatosis, inflammation, and fibrosis in the liver of mice
with the advanced stages of nonalcoholic steatohepatitis. Real-time quantitative polymerase chain reaction was used to measure the hepatic
expression of genes encoding (A) sterol regulatory element-binding protein-1c (Srebp1c), (B) fatty acid synthase (Fas), (C) apolipoprotein B (Apob), (D)
microsomal triglyceride transfer protein (Mttp), (E) plasminogen activator 1 (Serpine1), (F) cytochrome P450 2e1 (Cyp2e1), (G) transforming growth
factor-b (Tgfb), (H) procollagen1a2 (Col1a2). Results were normalized against 18S rRNA (Srebp1c, Fas, Serpine1, Cyp2e1, Tgfb, Col1a2) and beta-
actin(Apob,Mttp). Values are means 6 standard error. *p,0.05 versus the MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g007
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We conducted a global gene expression profile analysis to search
for direct actions of metformin in addition to the improved insulin
resistance. NASH model mice that had been treated with
metformin were clustered together with control mice and could
be separated from NASH model mice that did not receive
metformin treatment. Indeed, a PCA using the gene dataset
showed a remarkable shift in the distribution of NASH model mice
treated with metformin compared with untreated mice. A
canonical pathway analysis of the expression profiles revealed
that metformin effected significant alterations in gene expression
across at least 11 metabolic pathways, including those involved in
fatty acid and amino acid metabolism, such as the hepatic fibrosis/
hepatic stellate cell activation pathway.
Metformin decreased gene expression levels for Fas. FAS is a
key enzyme in fatty acid biosynthesis and is believed to be a
determinant of the maximal capacity of the liver to synthesize fatty
acids by de novo lipogenesis, because FAS catalyzes the last step in
the fatty acid biosynthetic pathway [27]. The metformin-induced
reduction of hepatic Fas mRNA levels may have contributed to the
improved hepatic steatosis in our model, as reported previously
[3].
The hepatic export of triglyceride and cholesterol is a major
determinant of steatosis as well as de novo lipogenesis. In the
present study, neither treatment with metformin nor MCD+HF
diet altered mRNA and protein levels for ApoB48, suggesting that
hepatic lipid export does not seem to be a major determinant of
hepatic steatosis altered by metformin treatment or MCD+HF
diet. However, further direct studies are needed to assess whether
metformin alters lipid export from the liver.
Metformin treatment decreased levels of gene expression for
Serpine-1 in the livers of MCD+HF diet-induced steatohepatitis in
mice. This result is compatible with previous studies in hepatoma
cell lines [28] and in the plasma of patients with type 2 diabetes
[29]. PAI-1 is an acute phase protein expressed under conditions
of inflammation [30–32] and contributes to the development of
organ fibrosis by inhibiting matrix metalloproteinase activity [33].
Furthermore, recent work has indicated that Serpine1 may have
lipid metabolism activity. Ma et al. found that Serpine12/2 mice
were protected from hepatic lipid accumulation in a model of
high-fat/high-carbohydrate diet-induced obesity [34]. Indeed, the
PAI-1/plasmin system also acts at the liver and might be
functionally important in liver extracellular matrix remodeling in
the NASH experimental model [3]. Bergheim et al. showed that
metformin ameliorated liver pathology by suppressing Serpine1
expression in an experimental alcoholic hepatitis mice model [35].
Importantly, they reported that metformin-mediated suppression
of PAI-1 is independent of AMPK pathway activation. In the
current study, microarray analysis showed no significant alteration
of gene expression profiles in the pathways involved in AMPK/
SREBP1c nor beta-oxidation (data not shown). These data suggest
that metformin improved liver pathology, at least partly, by
suppressing production of PAI-1 through the AMPK-independent
pathway. Further studies are needed to clarify the AMPK-
independent pathways that mediate the suppressive effect of
metformin on PAI-1 production in the hepatocytes.
Metformin also coordinately altered genes associated with acute
phase response signaling such as hemeoxygenase (Hmox1) in the
livers of MCD-induced steatohepatitis model mice. Heme
oxygenase 1 is a reductase enzyme that exerts anti-inflammatory
and anti-fibrotic effects [36]. These findings suggest that metfor-
min may improve steatohepatitis pathology by its anti-inflamma-
tory profile.
One limitation of this study is that it is not fully determined
whether metformin reverses hepatic fibrosis in diet-induced model
of NASH. We performed the measurement of hydroxyproline
contents and staining of Sirius Red to quantitate hepatic fibrosis
objectively. In the preventive experiments, these results clearly
indicated that metformin significantly prevented hepatic fibrosis
induced by MCD+HF diet. On the other hand, in the reversal
experiments, we could not observe longer time outcome of the
liver histology because administration of MCD+HF diet for more
than 8 weeks causes malnutrition-related death in mice. However,
decrease in the positive area of Sirius Red and down-regulation of
down-regulation of the genes involved in fibrogenesis such as Tgfb
and Col1a2 in the liver (Fig. 7G and 7H) suggest that metformin
has the potential to reverse the pre-existing fibrosis. Additional
experiments using other animal models for NASH are necessary to
confirm whether metformin reverses the pre-exist fibrosis.
Generally, drug administration experiments may lose body
weight in mice due to their toxic effects. However, in the current
study, food consumption was unchanged by treatment with
metformin in both preventive and reversal experiments, indicating
that the present doses of metformin were not toxic in terms of food
intake. These data suggest that metformin exerted beneficial
effects on MCD+HF diet-induced steatohepatitis independently of
food intake.
We showed that treatment with metformin rather increased the
levels of serum cholesterol (Table 1 and 3). As we previously
reported [3], steatohepatitis induced by MCD+HF diet results in
lower serum cholesterol levels probably due to impaired hapatic
function of cholesterol synthesis. Thus, in the present study, we
interpreted that metformin ameliorated liver function together
with liver pathology, and thereby recovered the decrease in serum
cholesterol levels.
Treatment with metformin for 4 weeks significantly decreased
mRNA levels for Srebp1c and Tgfb in the reverse experiment,
whereas this decrease was not observed in the preventive
experiment. The data of triglyceride content and hydroxyproline
Figure 8. Effects of metformin on the levels of proteins
involved in lipid metabolism in the liver of mice with the
advanced stages of nonalcoholic steatohepatitis. (A) Quantita-
tive data from densitometric analysis of Western blots from three
samples. (B) Representative blots for PAI-1, FAS, and, APOB are shown.
GAPDH is used as a control for protein loading. Values are the mean 6
standard error. *p,0.05 versus the MCD+HF diet group.
doi:10.1371/journal.pone.0043056.g008
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indicated that both hepatic steatosis and fibrosis were dramatically
improved by treatment with metformin for 8 weeks in the
preventive experiments. Hence, altered hepatic expression of
Srebp1c and Tgfb may be caused by attenuation of steatosis and
fibrosis. That is, normalized liver pathology masked the direct
effects of metformin on Srebp1c and Tgfb through the secondary
changes in the preventive experiments. Other possibility of altered
gene expression may be existence of the alternative pathway
leading to steatosis and fibrosis of the liver. Bergheim et al. showed
that metformin ameliorated liver pathology by suppressing PAI-
1expression in an experimental alcoholic hepatitis mice model
[35]. In this paper, genetic deletion of PAI-1 ameliorated not only
fibrosis, but also steatosis and inflammation in the liver. In the
present study, treatment with metformin for 4 weeks significantly
decreased mRNA levels for Srebp1c and Tgfb, but not for Serpine1 in
the reverse experiment, whereas metformin decreased mRNA
levels for Serpine1, but not for Srebp1c and Tgfb in the preventive
experiment. These findings suggest that metformin may amelio-
rate hepatic steatosis and fibrosis both via SREBP-1c- and TGF-b-
dependent pathways and via a PAI-1-mediated pathway. Anyway,
further time-course experiments should be required for confirm
direct effects of metformin on the genes involved in steatosis and
fibrosis to address these hypothesis.
In conclusion, metformin may prevent and reverse steatosis and
inflammation in a nondiabetic mouse model of steatohepatitis
possibly by downregulating pleiotropically lipogenic and fibrogen-
ic genes such as Serpine1 without affecting insulin resistance. The
present findings suggest the therapeutic potential of metformin in
human NASH even in patients without diabetes. Large scale
clinical trial should be required to test the hypothesis that
metformin reverses pathology of NASH in non-diabetic patients.
Author Contributions
Conceived and designed the experiments: TT. Performed the experiments:
YK HM S. Kurita YT MU NMN KK HA KH TK Y. Ni T. Otoda YZ.
Analyzed the data: YK TT KH TK YZ. Contributed reagents/materials/
analysis tools: KH TK. Wrote the paper: YK TT HM. Contributed to
discussion: YK TT HM T. Ota AF KM Y. Nakanuma S. Kaneko.
Reference
1. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, et al.
(1999) Association of nonalcoholic fatty liver disease with insulin resistance.
Am J Med 107: 450–455.
2. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, et al. (2010)
Histological course of nonalcoholic fatty liver disease in Japanese patients: tight
glycemic control, rather than weight reduction, ameliorates liver fibrosis.
Diabetes care 33: 284–286.
3. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, et al. (2007) Insulin
resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Gastroenterology 132: 282–293.
4. Belfort R, Harrison SA, Brown K, Darland C, Finch J, et al. (2006) A placebo-
controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
N Engl J Med 355: 2297–2307.
5. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, et al. (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects
with nonalcoholic steatohepatitis. Gastroenterology 135: 1176–1184.
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010)
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl JMed
362: 1675–1685.
7. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase
LKB1 mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science 310: 1642–1646.
8. Ota S, Horigome K, Ishii T, Nakai M, Hayashi K, et al. (2009) Metformin
suppresses glucose-6-phosphatase expression by a complex I inhibition and
AMPK activation-independent mechanism. Biochem Biophys Res Commun.
9. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its
anti-diabetic effects through inhibition of complex 1 of the mitochondrial
respiratory chain. Biochem J348 Pt 3: 607–614.
10. Misu H, Takamura T, Matsuzawa N, Shimizu A, Ota T, et al. (2007) Genes
involved in oxidative phosphorylation are coordinately upregulated with fasting
hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia 50: 268–
277.
11. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, et al. (2008)
Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of
Diabetic Patients. Obesity (Silver Spring).
12. Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, et al. (2006) Global
gene expression analysis in liver of obese diabetic db/db mice treated with
metformin. Diabetologia 49: 1647–1655.
13. Adachi M, Brenner DA (2008) High molecular weight adiponectin inhibits
proliferation of hepatic stellate cells via activation of adenosine monophosphate-
activated protein kinase. Hepatology 47: 677–685.
14. Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, et al. (2008) Adenosine
monophosphate-activated protein kinase modulates the activated phenotype of
hepatic stellate cells. Hepatology 47: 668–676.
15. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, et al. (2000) Metformin
reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6: 998–1003.
16. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001)
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes
50: 1844–1850.
17. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, et al. (2005) A
randomized controlled trial of metformin versus vitamin E or prescriptive diet in
nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082–1090.
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR
(1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the
histological lesions. Am J Gastroenterol 94: 2467–2474.
19. Stojanovic´ VR JI, Ugrenovic´ SZ, Vasovic´ LP, Zivkovic´ VS, Jocic´ MV, et al.
(2012) Morphometric Analysis of Nonsclerosed Glomeruli Size and Connective
Tissue Content during the Aging Process. ScientificWorldJournal 2012: 845046.
20. Uchinami H, Seki E, Brenner DA, D’Armiento J (2006) Loss of MMP 13
attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:
420–429.
21. Takamura T, Sakurai M, Ota T, Ando H, Honda M, et al. (2004) Genes for
systemic vascular complications are differentially expressed in the livers of type 2
diabetic patients. Diabetologia 47: 638–647.
22. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, et al.
(2010) A liver-derived secretory protein, selenoprotein P, causes insulin
resistance. Cell Metab 12: 483–495.
23. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a
pathogenic paradox. Cell Metab 7: 95–96.
24. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, et al. (1998) Efficacy
and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
N Engl J Med 338: 867–872.
25. Basu R, Shah P, Basu A, Norby B, Dicke B, et al. (2008) Comparison of the
effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action
in people with type 2 diabetes. Diabetes 57: 24–31.
26. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated
protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174.
27. Clarke SD (1993) Regulation of fatty acid synthase gene expression: an approach
for reducing fat accumulation. J Anim Sci 71: 1957–1965.
28. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I (1993) Plasminogen
activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2.
Metformin inhibits the stimulating effect of insulin. J Clin Invest 91: 2185–2193.
29. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, et al. (2008) The effect of
metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic
patients. Diabetes Res Clin Pract 81: 56–60.
30. Hamaguchi E, Takamura T, Shimizu A, Nagai Y (2003) Tumor necrosis factor-
alpha and troglitazone regulate plasminogen activator inhibitor type 1
production through extracellular signal-regulated kinase- and nuclear factor-
kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
J Pharmacol Exp Ther 307: 987–994.
31. Takeshita Y, Takamura T, Hamaguchi E, Shimizu A, Ota T, et al. (2006)
Tumor necrosis factor-alpha-induced production of plasminogen activator
inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant
human hepatocyte cell line. Metabolism 55: 1464–1472.
32. Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, et al. (2008)
Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in
tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 produc-
tion from hepatocytes. Eur J Pharmacol 579: 426–432.
33. Chapman HA (2004) Disorders of lung matrix remodeling. J Clin Invest 113:
148–157.
34. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, et al. (2004) Prevention
of obesity and insulin resistance in mice lacking plasminogen activator inhibitor
1. Diabetes 53: 336–346.
35. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, et al. (2006) Metformin
prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen
activator inhibitor-1. Gastroenterology 130: 2099–2112.
36. Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, et al. (2009) Analysis of
hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic
fatty liver disease. Hepatol Res 39: 366–373.
Metformin Reverses Inflammation in NASH
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e43056
